https://www.alphaview.kr/news/40977-berkshire-hathaway-to-acquire-taylor-morrison-home-corporation-for-85-billion AlphaView ko 2026-05-31T21:30:00.000Z Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion https://www.alphaview.kr/news/40976-ihuman-inc-announces-acquisition-of-businesses-and-assets-related-to-all-knowled AlphaView ko 2026-05-31T17:03:00.000Z iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo https://www.alphaview.kr/news/40975-cpkc-to-maintain-rail-operations-across-canada-during-ibew-strike AlphaView ko 2026-05-31T15:18:00.000Z CPKC to maintain rail operations across Canada during IBEW strike https://www.alphaview.kr/news/40974-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-pivotal-data-show-strong-and AlphaView ko 2026-05-31T13:29:00.000Z RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited https://www.alphaview.kr/news/40973-johnson-johnsons-phase-3-prostate-cancer-study-shows-erleada-apalutamide-before AlphaView ko 2026-05-31T13:27:00.000Z Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm https://www.alphaview.kr/news/40972-lillys-retevmo-selpercatinib-demonstrated-an-83-reduction-in-the-risk-of-disease AlphaView ko 2026-05-31T13:01:00.000Z Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer https://www.alphaview.kr/news/40971-grail-presents-pathfinder-2-results-of-more-than-35000-participants-showing-the AlphaView ko 2026-05-31T13:00:00.000Z GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting https://www.alphaview.kr/news/40970-six-flags-fiesta-texas-unleashes-werewolf-gorge-the-worlds-longest-family-launch AlphaView ko 2026-05-31T03:15:00.000Z SIX FLAGS FIESTA TEXAS UNLEASHES WEREWOLF GORGE, THE WORLD'S LONGEST FAMILY LAUNCH ROLLER COASTER https://www.alphaview.kr/news/40968-precigen-presents-new-long-term-durability-data-for-papzimeos-recently-granted-s AlphaView ko 2026-05-30T19:30:00.000Z Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years https://www.alphaview.kr/news/40969-whitehawk-therapeutics-presents-realworld-analysis-confirming-sez6-as-a-highly-e AlphaView ko 2026-05-30T19:30:00.000Z Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 https://www.alphaview.kr/news/40967-grail-reports-full-results-from-nhs-galleri-trial-demonstrating-substantial-redu AlphaView ko 2026-05-30T13:00:00.000Z GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting https://www.alphaview.kr/news/40966-humana-investigation-continued-kahn-swick-foti-llc-continues-to-investigate-the AlphaView ko 2026-05-30T03:00:00.000Z Humana Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humana Inc. - HUM https://www.alphaview.kr/news/40965-clps-incorporation-receives-nasdaq-notification-regarding-minimum-bid-price-requ AlphaView ko 2026-05-30T01:16:00.000Z CLPS Incorporation Receives Nasdaq Notification Regarding Minimum Bid Price Requirements